Adaptive biotechnologies stock.

Traditional biotechnology is the use of natural organisms by humans to create or modify foods or other useful products. Examples of traditional biotechnology include using yeasts for fermentation and practicing selective seed collection to ...Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Ms. Taylor ADPT stock SEC Form 4 insiders trading. Stacy has made over 25 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 18,878 units of ADPT stock worth $162,162 on 6 March 2023.. The largest trade she's ever made was exercising 19,580 units of Adaptive …The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.

Future price of the stock is predicted at 0$ (-100% ) after a year according to our prediction system. This means that if you invested $100 now, your current ...

Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAdaptive Biotechnologies Corporation Common Stock (ADPT) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Live After-Hours Key Data Bid Price and Ask Price …

Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get the latest Adaptive Biotechnologies Corp (ADPT) real-time quote, historical performance, charts, and other financial information to help you make more informed …Andris Zoltners ADPT stock SEC Form 4 insiders trading. Andris has made over 2 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently Andris sold 345,000 units of ADPT stock worth $9,142,500 on 28 January 2020.. The largest trade Andris's ever made was selling 345,000 units of …

Piper Sandler has a $15 target price on Adaptive Biotechnologies stock. The consensus target is $12.29, and shares last traded on Friday at $8.39. ALSO READ: 5 Warren Buffett Dividend Stocks to ...

... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...

SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ...... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued. Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. Date.Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …

Adaptive Biotechnologies stock soars 90% after ringing Nasdaq opening bell following $300M IPO. by James Thorne on June 27, 2019 at 8:08 am June 27, 2019 at 3:25 pm. Share 66 Tweet Share Reddit Email.View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Adaptive Biotechnologies. Use the PitchBook Platform to explore the ...SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...Whatever you make of her stock choices, Woo. ... Adaptive Biotechnologies is a pioneering commercial-stage biotech company at the forefront of immune-driven medicine. By harnessing genetic data ...Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.Adaptive Biotechnologies ( ADPT) reported Q3 2023 earnings per share (EPS) of -$0.35, missing estimates of -$0.34 by 2.64%. In the same quarter last year, Adaptive Biotechnologies 's earnings per share (EPS) was -$0.32. Adaptive Biotechnologies is expected to release next earnings on 02/19/2024, with an earnings per share (EPS) …

Adaptive Biotechnologies shares are trading down 2.6% at $37.12 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete ...

SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.Adaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from …Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20. Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.

Apr 11, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.

The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price.

At present, SG Americas Securities LLC holds a total of 76,854 shares of Adaptive Biotechnologies Co., compared to its previous ownership of 28,962 shares. The acquisition of an additional 47,892 shares during the first quarter highlights the firm’s belief in the long-term prospects and value of Adaptive Biotechnologies’ stock.Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ...Jun 2, 2023 · SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ... Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price.Nov 9, 2023 · Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ... Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...Adaptive Biotechnologies Corp (NASDAQ: ADPT)’s stock price has soared by 3.44 in relation to previous closing price of 4.03. Nevertheless, the company has seen a gain of 18.77% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, […]

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives’ for key business lines With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease (MRD) and Immune Medicine …The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...Instagram:https://instagram. xbi holdingsnasdaq lfvnbenzinga premarket gainershow much is 100 shares of royal caribbean stock Mar 31, 2023 · As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ... Sep 26, 2023 · Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ... cigna plus savings dental plantoronto dominion bank stock May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ... how much is orthodontic insurance Apr 15, 2022 · Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. The company's stock has been smashed in the last year losing over two-thirds of its share price. Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...Information on stock, financials, earnings, subsidiaries, investors, and executives for Adaptive Biotechnologies. Use the PitchBook Platform to explore the ...